Fungal Testing Kits Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Fungal Testing Kits Market Trends and Insights

Rising Burden of Invasive Fungal Infections

The growing burden of invasive fungal infections is a core demand driver for the fungal testing kits market. A 2024 review estimated 6.5 million life-threatening invasive fungal infections each year and 3.8 million related deaths.^{[1]“Global Incidence and Mortality of Severe Fungal Disease,”} Critically ill populations carry a particularly high risk, and a 2025 review reported more than 1.66 million deaths in critical-care settings. Untreated invasive candidiasis can have a 30-day mortality of 35% to 45%, making delayed diagnosis difficult to accept in acute care. Traditional culture methods can require 3 to 7 days, so hospitals increasingly favor molecular and antigen-based testing. This shift supports higher-value testing workflows and limits the need for vendors to use large price concessions to build volume.

Mycotoxin Compliance and Climate-Related Contamination Risk

Food safety rules are creating recurring demand for fungal testing kits across agricultural supply chains. EU Implementing Regulation 2023/2782 sets sampling and analysis methods for mycotoxin controls, and later amendments extended its coverage to additional food matrices. ISO 23719:2025 established a validated UHPLC-MS/MS method for measuring 17 mycotoxins in cereals and cereal products.^{[2]“ISO 23719:2025 Cereals and Cereal Products, Determination of 17 Mycotoxins by UHPLC-MS/MS,"} These rules encourage laboratories to replace single-toxin testing with systems that can assess several analytes in one run. Climate-related changes in aflatoxin and fumonisin contamination add pressure in maize- and wheat-dependent supply chains across Southern and Eastern Europe. The result is a clearer divide between lower-cost rapid tests and laboratory-grade methods for high-throughput inspection.

Faster Culture-Independent Diagnostics and Resistance Surveillance

Culture-based diagnostics often have sensitivity below 50% for several invasive infections, which creates a need for faster alternatives. The fungal testing kits market is therefore moving toward qPCR, LAMP, and CRISPR-based formats that can identify pathogens without waiting for culture growth. A 2026 study described an automated real-time PCR platform that identified 4 major Aspergillus species within hours. A separate 2026 study reported digital CRISPR diagnostics that quantified Candida auris and identified resistance mutations within 40 minutes.^{[3]“Digital CRISPR-Based Diagnostics for Quantification of Candida auris and Resistance Mutations,”} The combined need for identification and resistance profiling is encouraging integrated testing workflows, subject to reimbursement support.

Decentralized and Near-Patient Testing

Testing is gradually shifting from central reference laboratories toward near-patient settings. This supports stewardship programs that need results quickly enough to guide treatment choices. Zepto Life Technology launched the FungiFlex Mold Panel in January 2026, a plasma cell-free DNA test that detects 14 mold species in under 24 hours through a CLIA reference laboratory. Roche completed its LumiraDx acquisition in 2024, adding point-of-care technology to its diagnostics portfolio. Diagnostic laboratories are growing partly because they can support near-patient satellite systems. 

Cost and Standardization Barriers for Advanced Workflows

MALDI-TOF mass spectrometry, whole-genome sequencing, and metagenomic sequencing provide details that conventional culture methods cannot match. Their instrument, reagent, and operating costs still limit uptake in many settings. The World Health Organization stated in 2025 that available diagnostics are often slow, inaccurate, expensive, and limited in scope, especially in low- and middle-income countries. This cost gap creates a two-tier pattern, with advanced systems adopted by high-income hospitals while other facilities rely on immunoassays or culture. Incomplete standards for pan-fungal and metagenomic assays also make multisite validation and regulatory review harder. Multiplexed tests that lower the cost per result may ease both barriers by combining species detection and resistance markers in a single run.

Infrastructure Gaps and Clinical Interpretation Limits

Laboratory capacity remains a major restraint in regions with a high fungal disease burden. The WHO reported that many fungal diseases are absent from national health plans and antimicrobial resistance frameworks in low- and middle-income countries. Cold-chain requirements for some reagents can further complicate distribution in tropical and resource-limited areas. IMMY appointed Intralink in 2025 to develop a 3-year expansion plan in India, showing the need for local distribution structures rather than product availability alone. Clinical teams also need to distinguish colonization from active infection, especially in critical care and oncology. These limits can delay appropriate use even when a test is available, keeping adoption uneven through 2031.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Application: Clinical Diagnostics Leads While Environmental Monitoring Advances

Clinical diagnostics held 46.37% of the fungal testing kits market share in 2025. The segment is supported by use in intensive care, oncology, and transplant settings, where fast identification influences antifungal treatment decisions. The WHO identified clinical settings as a primary destination for diagnostic investment because of the mortality associated with critical-priority pathogens such as Candida auris and Aspergillus fumigatus. Food and agriculture is the second-largest application areas. Its demand is supported by the required mycotoxin surveillance under EU rules and FDA action-level enforcement. These obligations make testing a recurring operational need rather than a discretionary purchase.

Environmental monitoring is forecast to grow at a 8.98% CAGR through 2031. The fungal testing kits market size for this application is supported by monitoring needs in pharmaceutical cleanrooms, water systems, and air-handling units. Mold risk in built environments is also receiving greater attention as contamination conditions change. ISO/IEC 17025 accreditation requirements and USP <797> standards are pushing facilities beyond periodic culture plates toward methods with quantitative outputs. Veterinary and cosmetic safety uses remain smaller applications. They are attracting early innovation activity, including testing in food-producing animals where antifungal resistance is emerging as a regulatory concern.

By Technology: Molecular Diagnostics Holds the Largest Position and Immunoassays Grow Fastest

Molecular diagnostics held 38.74% of technology revenue in 2025. PCR-based systems offer results within hours and species-level resolution that culture cannot usually deliver at the same speed. The fungal testing kits market includes qPCR, LAMP, digital droplet PCR, and CRISPR-based assays. A 2025 review described portable molecular tools that support near-real-time fungal identification and resistance prediction. QIAGEN launched its CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel in April 2026, detecting 20 fungal and gram-positive targets and 10 resistance markers in 1 hour from positive blood cultures. Such panels combine identification and resistance information in one workflow.

Immunoassays are forecast to grow at a 9.23% CAGR through 2031. Their demand reflects the use of beta-D-glucan and galactomannan assays, which can provide infection signals earlier than culture. They can also avoid invasive specimen collection in some settings. The fungal testing kits market growth in immunoassays is supported by their fit with routine clinical screening and decentralized testing. The fungal testing kits market retains substantial culture-kit and consumable volumes in food and environmental testing. Their low cost and simple operation remain appropriate for routine monitoring work.

By Test Type: Molecular Tests Lead and Susceptibility Testing Becomes More Important

Molecular tests held 32.46% of test-type revenue in 2025. qPCR and next-generation sequencing formats are becoming central to invasive fungal disease assessment in tertiary care. China issued the national standard WS/T 497-2026 for laboratory diagnosis of invasive fungal disease, which is expected to support more consistent molecular testing protocols across medical institutions. Chromogenic and culture-based tests remain important in high-throughput screening. Thermo Fisher Scientific, Inc. launched Brilliance Candida 2 Agar in Europe and Spectra Candida Agar in the United States in March 2026, supporting visual differentiation of Candida species, including Candida auris. This shows that the fungal testing kits market continues to support culture innovation, where a focused clinical use remains clear.

Antifungal susceptibility tests are forecast to grow at a 9.84% CAGR through 2031. The fungal testing kits market is benefiting from the clinical need to identify resistance patterns in Candida auris. U.S. Candida auris clinical cases exceeded 6,197 in 2024, and the FDA allocated FY2026 funding to advance susceptibility test criteria for the pathogen. EUCAST published Candida auris clinical breakpoints in 2025, which supports validation of standardized commercial kits. Many hospitals that offer susceptibility testing still send work to external laboratories. Compact automated systems for on-site use can address this remaining gap.

By Sample Type: Blood Leads While Urine Testing Meets Noninvasive Demand

Blood-based testing held 36.28% of sample-type revenue in 2025. Blood is central to the diagnosis of invasive candidiasis and systemic aspergillosis because circulating cell-free DNA and antigens can appear before culture positivity. The FungiFlex Mold Panel detects 14 mold species from plasma in under 24 hours. These platforms can reduce reliance on more invasive procedures, including bronchoalveolar lavage. Skin samples retain meaningful use in primary care and dermatology. The CDC estimated 9 million outpatient visits annually in the United States for superficial fungal infections, including ringworm and nail disease.

Urine-based testing is forecast to grow at a 10.35% CAGR through 2031. Its use is expanding for cryptococcal antigen screening in HIV-positive populations in resource-limited settings. Urine testing avoids venipuncture and lowers biosafety needs, which can support community-level screening. The fungal testing kits market also includes urine-matrix assays for ochratoxin A and aflatoxin exposure monitoring. Vaginal secretion samples serve dermatology, gynecology, and oral health applications. The fungal testing kits market also supports veterinary uses through other samples, where specialty developers may find higher-value opportunities.

By End User: Hospitals and Clinics Lead While Diagnostic Laboratories Expand

Hospitals and clinics held 42.63% of end-user revenue in 2025. Their position reflects the need for on-site or nearby testing for inpatient fungal infection management. Academic medical centers often operate dedicated mycology laboratories that serve as regional reference sites. These facilities use advanced mass spectrometry and molecular systems for complex cases. Outpatient diagnosis and surveillance are gradually moving some work toward specialized laboratories. This transfer does not reduce the fungal testing kits market demand because hospitals continue to initiate testing and manage treatment decisions.

Diagnostic laboratories are forecast to grow at an 11.46% CAGR through 2031. The fungal testing kits market size for this channel is supported by the externalization of molecular and susceptibility workflows from hospital laboratories. Specialized facilities can achieve better instrument utilization and purchasing efficiency for consumables. Research institutes are smaller users but remain important early adopters of metagenomic and pan-fungal methods. Environmental monitoring firms, food manufacturers, and veterinary services make up the remaining end-user base. Their repeat purchases are often linked to compliance schedules and routine quality-control programs.

Geography Analysis

North America held 36.72% of the fungal testing kits market share in 2025. The region has established clinical laboratory networks, reimbursement mechanisms for molecular tests, and active surveillance through the CDC and the Antimicrobial Resistance Laboratory Network. Candida auris clinical cases in the United States exceeded 6,197 in 2024, prompting faster screening and species-specific testing in healthcare settings. The United States accounts for most regional demand, while Canada and Mexico are increasing investment in tertiary-hospital diagnostics. The July 2025 transaction involving Waters and BD's Biosciences and Diagnostic Solutions business was valued at USD 17.5 billion and is expected to focus the combined business on regulated, high-volume diagnostic workflows.

Europe held the second-largest regional position in 2025. Germany is an anchor market, and the EU IVDR transition favors manufacturers that can meet Notified Body compliance requirements. The transition raises the quality threshold for fungal kits, while creating barriers for smaller companies with products subject to revised classification. EU mycotoxin rules provide a legally enforceable base of recurring food-safety testing across Germany, France, Italy, and Spain. QIAGEN launched the QIAstat-Dx BCID GN Plus AMR Panel in Europe in July 2026, extending bloodstream testing coverage to 33 pathogen targets and 28 resistance markers across its panels. This regulatory setting makes certification a key condition for fungal testing kits market commercialization of broad syndromic panels.

Asia-Pacific is forecast to grow at a 13.67% CAGR through 2031. China has established national laboratory requirements for invasive fungal disease through WS/T 497-2026, creating a clearer pathway for commercial procurement. India offers substantial potential because of healthcare expansion and a large population vulnerable to cryptococcal meningitis. Japan, South Korea, and Australia add demand through advanced diagnostics and food safety systems. The Middle East and Africa are supported by healthcare modernization in GCC states, but laboratory infrastructure and cold-chain gaps remain. South America also offers growth through Brazil's agricultural sector and its need for mycotoxin compliance testing.